Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The team from the University of California found that immunization with either Pfizer-BioNTech’s BNT162b2 or Moderna’s mRNA-1273 vaccine-induced enrichment of spike-specific B cells.
The viral spike protein mediates the initial stage of the SARS-CoV-2 infection process and is the primary target of antibodies following natural infection or vaccination.
Ilhem Messaoudi and colleagues say that vaccination also activated CD4 T cells and induced robust antigen-specific polyfunctional CD4 T cell responses.
Furthermore, clonally expanded CD8 T cells were observed in all vaccine recipients.
A pre-print version of the research paper is available on the bioRxiv* server, while the article undergoes peer review.
Vaccination and infection provide two different pathways to immunity
Since the COVID-19 outbreak first began in December 2019 in Wuhan, China, intense global efforts to rapidly develop effective vaccines against the causative agent SARS-CoV-2 have led to the emergency use authorization of several vaccines.
These include the messenger RNA- (mRNA) based vaccines developed by Pfizer (BNT162b2) and Moderna (mRNA-1273). Findings from clinical trials indicated that a 95% maximal protection is achieved within 1 to 2 months following the second dose of either vaccine, including protection against several circulating SARS-CoV-2 variants of concern.
However, the mechanisms by which these vaccines elicit long-lasting cellular immune responses to the virus remain poorly understood.
Natural infection and vaccination provide two different pathways to immunity, which studies have previously shown to be characterized by distinct T and B cell responses.
“Additional studies that integrate functional, transcriptional, and repertoire analysis of the memory immune cell response to COVID-19 mRNA vaccination are needed,” writes Messaoudi and colleagues.
What did the researchers do?
The team used single-cell RNA sequencing and functional assays to assess humoral (antibody) and cellular responses to two doses of either the Pfizer-BioNTech or Moderna mRNA vaccine (14 days following a second dose) in four individuals. The results were compared with the immune responses observed in three convalescent individuals who had experienced asymptomatic or mild infection.
What did the study find?
Both infection and vaccination induced anti-SARS-CoV-2 binding and neutralizing antibodies.
These antibodies were detected as early as two weeks following a first vaccine dose, with levels increasing several-fold after a second dose.
While neutralizing antibody titers following the first vaccine dose were comparable to those among convalescent individuals, significantly higher levels were observed in the vaccinees following the booster dose.
However, several important B cell adaptations were shared between vaccinees and convalescent individuals.
Analysis by flow cytometry revealed a reduction in the level of naïve B cells, but an expansion of memory B cells in both groups.
Additionally, single-cell RNA sequencing showed a reduction in IgA+ memory B cells following vaccination, a finding that has recently been described for convalescent individuals.
When covid-19 struck Europe in March 2020, hospitals were plunged into a health crisis that was still badly understood. “Doctors really didn’t have a clue how to manage these patients,” says Laure Wynants, an [...]
Pfizer found to be 88 per cent effective at preventing symptomatic disease from delta variant. Two doses of Pfizer-BioNTech or AstraZeneca-Oxford's COVID-19 vaccines are nearly as effective against the highly transmissible delta coronavirus variant [...]
South African pharmaceutical company Aspen said Monday it was releasing its first batch of African-produced COVID-19 vaccines under a licensing deal with the US giant Johnson & Johnson. The Durban-based company said the first [...]
Since the coronavirus pandemic shut down the world, scientists have clamored to develop vaccines to prevent the spread and medicines that will cure the sick. But a virus’ main goal is to replicate and [...]
The highly transmissible delta variant of SARS-CoV-2, the coronavirus causing the disease COVID-19, is now present in 124 countries and will become the dominant strain globally in the coming months as it is outcompeting [...]
Scientists have backed proposals for Covid boosters in the autumn after blood tests on hundreds of people revealed that protective antibodies can wane substantially within weeks of second vaccine shots being given. Falls in [...]
Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall [...]
CSIRO, Australia's national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern. Published [...]
Podcast – Nanovisaging 2040 How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit Humanity
Frank Boehm (NanoApps Medical Inc. Founder) in discussion with Nana Kay in a Wealth Secrets podcast. EP 19. Nanovisaging 2040. From Nana Kay: Nanovisaging 2040: How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit [...]
Canada, like several other countries, has been mixing and matching COVID-19 vaccines for weeks amid safety concerns over the AstraZeneca shot. On Monday, the chief scientist at the World Health Organization (WHO) cautioned against that approach, calling [...]
Scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19. However, the study was performed [...]
A recent study by scientists from Japanese universities has shown that the shape of cell-derived nanoparticles, known as "extracellular vesicles" (EVs), in body fluids could be a biomarker for identifying types of cancer. In [...]
An important lesson for vaccine design Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not [...]
1. How COVID-19 is affecting the globe Confirmed cases of COVID-19 have passed 185 million globally, according to Johns Hopkins University. The number of confirmed deaths stands at more than 4 million. More than 3.29 [...]
The World Health Organization (WHO) has added another COVID strain to its list of coronavirus variants to keep an eye on: the COVID-19 Lambda variant. This particular variant has now spread to more than two dozen [...]